Eli Lilly share price boosted by obesity data for diabetes treatment

The Eli Lilly share has performed better than the broad S&P 500 index so far this year. After positive obesity data was announced for tirzepatide on Tuesday, the share got another boost.

Photo: Mike Blake/REUTERS / X00030

US-based Eli Lilly has had the wind in its sails on the stock market this week.

On Monday, the company released weight loss data on trial participants receiving tirzepatide, which is already an approved treatment for diabetes marketed under the name Mounjaro.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs